NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization94.13 mln
Float76.19 mln
Earnings Date10/29/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.7
Likely manipulated
1-Year Forecast
5.28
Transformational upside
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.02
Debt-free
Pre-Tax Margin
-7,884%
Severely loss-making
Business Description
Cardiff Oncology is a San Diego-based biotechnology company focused on developing new cancer treatments. Its primary asset is Onvansertib, an oral drug targeting a protein called polo-like kinase 1, which is being studied in patients with colorectal cancer carrying specific genetic mutations known as RAS or KRAS. The company is running several clinical trials across multiple cancer types, including pancreatic cancer, lung cancer, breast cancer, and leukemia. Founded in 1999 and formerly known as Trovagene, Cardiff Oncology continues to advance its pipeline through partnerships with researchers and multi-center study programs.
